Abstract:Myasthenia gravis (MG) is a rare, treatable, antibody-mediated disease characterized by fatigable muscle weakness of extraocular muscles (EOMs) and non-ocular skeletal muscles. The antibodies are directed against muscle-endplate proteins, most frequently the acetylcholine receptor (AChR) alpha-subunit. Although most MG patients respond to immunosuppressive treatment, some individuals, frequently with African-genetic ancestry, develop treatment-resistant ophthalmoplegia (OP-MG). Although the underlying pathogenetic mechanisms of OP-MG remain unknown, experimental rodent models of MG showed upregulation of genes involved in oxidative metabolism in muscles. EOMs are highly dependent on oxidative metabolism. We opportunistically sampled EOM-tendons of two rare OP-MG patients (and non-MG controls) undergoing re-alignment surgery, and established ocular fibroblast cultures. Metabolic assays were performed on these live cells to assess real-time differences in energy metabolism. To study the cellular bioenergetic profiles in the context of MG, we exposed the cultures to homologous 5% MG sera for 24 h, vs. growth media, from two independent MG patients (with circulating AChR-antibodies) and five controls without MG, and estimated the fold change in oxygen consumption rates in response to three compounds which inhibit different mitochondrial chain complexes. Quantitative PCR (qPCR) was performed in cells before and after MG sera exposure, to assess transcript levels of mitochondrial genes, PDK4, ANGPTL4 and UCP3, which were altered in experimental MG. In response to the mitochondrial stressors, basal oxidative metabolism parameters were similar between OP-MG and control fibroblasts (p = 0.81). However, after exposure to MG sera, bioenergetic parameters (oxygen consumption rate as an indicator of oxidative phosphorylation; extracellular acidification rate as an indicator of glycolysis), were induced to higher levels in OP-MG fibroblasts compared to controls (2.6-fold vs 1.5-fold; p = 0.031) without evidence of mitochondrial insufficiency in the OP-MG ocular fibroblasts. In support of the bioenergetic responses to the same MG sera, gene transcripts of PDK4 and ANGPLT4 in ocular fibroblasts also showed significant upregulation (p ≤ 0.041), but similarly in OP-MG and control cases. Taken together we showed similar basal and metabolic adaptive responses after exposure to mitochondrial inhibitors in ocular fibroblasts derived from OP-MG cases and controls, although the OP-MG cells showed greater activation in response to MG conditions. These pilot results in orbital-derived tissues provide support for myasthenic-induced changes in cellular metabolism and evidence that orbital fibroblasts may be useful for dynamic bioenergetic assessments.

Expression of Tfh Cells and Molecules in Peripheral Blood from OMG and GMG Patients

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

Augmentation Of Circulating Follicular Helper T Cells And Their Impact On Autoreactive B Cells In Myasthenia Gravis

Study of circulating Th17 cells and associated cytokines in myasthenia gravis

Comparison of Peripheral Blood Regulatory T Cells and Functional Subsets Between Ocular and Generalized Myasthenia Gravis

Decrease of CD4+CD25highFoxp3+ regulatory T cells and elevation of CD19+BAFF-R+ B cells and soluble ICAM-1 in myasthenia gravis

The Change and Relevant Significance of Th1/Th2/Th17 Cytokines in Myasthenia Gravis

Mitochondrial bioenergetics in ocular fibroblasts of two myasthenia gravis cases

Increased Frequency of Thymic T Follicular Helper Cells in Myasthenia Gravis Patients with Thymoma

Circulating Regulatory T Cells and B Cell-Activating Factor Receptor on B Cells in Patients with Myasthenia Gravis

Effect of Follicular T Helper and T Helper 17 Cells-Related Molecules on Disease Severity in Patients with Myasthenia Gravis

Rhizosphere soil nitrogenase (C2H2 reduction) as influenced by plant density in intermediate deep water rice

Dynamic study of circulating CD_4~+CD_(25)~(high) T cells in myasthenia gravis

Stereotypic T cell receptor clonotypes in the thymus and peripheral blood of Myasthenia gravis patients

Imbalance of Th17 and Tregs in thymoma may be a pathological mechanism of myasthenia gravis

Differential Gut Microbiota and Fecal Metabolites Related With the Clinical Subtypes of Myasthenia Gravis

Plasma Levels and Clinical Significance of Complement Activation Products in Generalized Myasthenia Gravis Patients with Acetylcholine Receptor Antibodies

Circulating CD45RA-Foxp3++ Treg cells serve as a biomarker for predicting minimal clinical manifestations status of myasthenia gravis

Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Weighted gene coexpression network analysis and machine learning for the determination of tfh cell and B cell infiltrating biomarkers in thymoma-associated myasthenia gravis

Associated Hyperthyroidism in Myasthenia Gravis